Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy

被引:814
|
作者
Liao, Wei [1 ,2 ]
Lin, Jian-Xin [1 ,2 ]
Leonard, Warren J. [1 ,2 ]
机构
[1] NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA
[2] NHLBI, Ctr Immunol, NIH, Bethesda, MD 20892 USA
关键词
REGULATORY T-CELLS; RECEPTOR-ALPHA-CHAIN; SEVERE COMBINED IMMUNODEFICIENCY; GAMMA-CHAIN; BETA-CHAIN; IL-2; RECEPTOR; GENE-EXPRESSION; MONOCLONAL-ANTIBODY; GROWTH-FACTOR; IFN-GAMMA;
D O I
10.1016/j.immuni.2013.01.004
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Interleukin-2 (IL-2) is a pleiotropic cytokine produced after antigen activation that plays pivotal roles in the immune response. Discovered as a T cell growth factor, IL-2 additionally promotes CD8(+) T cell and natural killer cell cytolytic activity and modulates T cell differentiation programs in response to antigen, promoting naive CD4(+) T cell differentiation into T helper 1 (Th1) and T helper 2 (Th2) cells while inhibiting T helper 17 (Th17) and T follicular helper (Tfh) cell differentiation. Moreover, IL-2 is essential for the development and maintenance of T regulatory cells and for activation-induced cell death, thereby mediating tolerance and limiting inappropriate immune reactions. In this review, we focus on the molecular mechanisms and complex cellular actions of IL-2, its cooperative and opposing effects with other cytokines, and how both promoting and blocking the actions of IL-2 are being utilized in clinical medicine.
引用
收藏
页码:13 / 25
页数:13
相关论文
共 50 条
  • [41] Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy
    Samuel C Wagner
    Boris Markosian
    Naseem Ajili
    Brandon R Dolan
    Andy J Kim
    Doru T Alexandrescu
    Constantin A Dasanu
    Boris Minev
    James Koropatnick
    Francesco M Marincola
    Neil H Riordan
    Journal of Translational Medicine, 12
  • [42] PERSPECTIVES ON INTERLEUKIN-2 IMMUNOTHERAPY FOR COLON-CANCER
    CHANG, AE
    GASTROENTEROLOGY, 1994, 107 (06) : 1890 - 1892
  • [43] MODULATION OF ALLOTRANSPLANTATION TOLERANCE INDUCTION BY INTERLEUKIN-1 AND INTERLEUKIN-2
    HOLAN, V
    JOURNAL OF IMMUNOGENETICS, 1988, 15 (5-6): : 331 - 337
  • [44] CANCER-IMMUNOTHERAPY USING INTERLEUKIN-2 AND INTERLEUKIN-2-ACTIVATED LYMPHOCYTES
    ROSENBERG, SA
    LOTZE, MT
    ANNUAL REVIEW OF IMMUNOLOGY, 1986, 4 : 681 - 709
  • [45] SERUM INTERLEUKIN-2 RECEPTOR RESPONSES TO IMMUNIZATION
    WARD, MM
    HALL, RP
    PISETSKY, DS
    CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1990, 57 (01): : 120 - 124
  • [46] Biological significance of interleukin-6 secretion on cancer immunotherapy with interleukin-2
    Lissoni, P
    Fumagalli, L
    Barni, S
    DiFelice, G
    Ardizzoia, A
    Maiorca, F
    Tancini, G
    INTERNATIONAL JOURNAL OF IMMUNOTHERAPY, 1996, 12 (3-4): : 49 - 52
  • [47] INTERLEUKIN-2 TREATMENT POTENTIATES INDUCTION OF ORAL TOLERANCE
    RIZZO, LV
    MILLERRIVERO, NE
    CHAN, CC
    WIGGERT, B
    NUSSENBLATT, RB
    CASPI, RR
    FASEB JOURNAL, 1994, 8 (04): : A476 - A476
  • [48] DECREASE IN CHOLESTEROL LEVELS DURING THE IMMUNOTHERAPY OF CANCER WITH INTERLEUKIN-2
    LISSONI, P
    BRIVIO, F
    PITTALIS, S
    PEREGO, MS
    ARDIZZOIA, A
    MAURI, O
    BARNI, S
    CRISPINO, S
    TANCINI, G
    BRITISH JOURNAL OF CANCER, 1991, 64 (05) : 956 - 958
  • [49] Interleukin-2 immunotherapy and AIDS-related cytomegalovirus retinitis
    Dix, RD
    Cousins, SW
    CURRENT HIV RESEARCH, 2004, 2 (04) : 333 - 342
  • [50] Marrow stromal cells for interleukin-2 delivery in cancer immunotherapy
    Stagg, J
    Lejeune, L
    Paquin, A
    Galipeau, J
    HUMAN GENE THERAPY, 2004, 15 (06) : 597 - 608